Treatment of status epilepticus with midazolam in the critical care setting

International Journal of Clinical Practice

Volumn 54, Issue 1, 2000, Pages 30-35

  Hanley Jr , Daniel F ^a   Pozo, M ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; MIDAZOLAM;

CELL DEATH; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SOLUBILITY; EPILEPTIC STATE; HUMAN; HYPOTENSION; INTENSIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

BARBITURATES; BENZODIAZEPINES; CRITICAL CARE; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; MIDAZOLAM; STATUS EPILEPTICUS; TREATMENT REFUSAL;

EID: 0033967522     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. DeLorenzo RJ, Pellock JM, Towne AR et al. Epidemiology of status epilepticus. J Clin Neurophysiol 1995; 12: 316-325.
2. Slovis CM. ED management of unstable patients with status epilepticus. Emerg Med Rep 1989; 10: 67-72.
3. Korttila K, Aromaa U. Venous complications after intravenous injections of diazepam, flunitrazepam, thiopentone and etomidate. Acta Anesthesiol Scand 1980; 24: 227-230.
4. Gerecke M. Chemical structure and properties of midazolam compared with other benzodiazepines. Br J Clin Pharmacol 1983; 16: 11S-16S.
5. Gamble JAS, Dundee JW, Assaf RAE. Plasma diazepam levels after single dose oral and intramuscular administration. Anesthesia 1975; 30: 164-169.
6. Raines A, Henderson TR, Swinyard EA et al. Comparison of midazolam and diazepam by the intramuscular route for the control of seizures in a mouse model of status epilepticus. Epilepsia 1990; 31: 313-317.
7. Dieckmann RA. Rectal diazepam for prehospital pediatric status epilepticus. Ann Emerg Med 1994; 23: 216-224.
8. Hauser WA. Status epilepticus: epidemiologic considerations. Neurology 1990; 40(suppl 2): 9-13.
9. DeLorenzo RJ, Towne AR, Pellock JM et al. Status epilepticus in children, adults, and the elderly. Epilepsia 1992; 33(suppl 4): S15-S25.
10. Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology 1993; 43: 483-488.
11. Scholtes FB, Renier WO, Meinardi H. Generalized convulsive status epilepticus: causes, therapy, and outcome in 346 patients. Epilepsia 1994; 35: 1104-1112.
12. Roberts MR, Eng-Bourquin J. Status epilepticus in children. Pediatr Emergency 1995; 13: 489-507.
13. Towne AR, Pellock JM, Ko D et al. Determinants of mortality in status epilepticus. Epilepsia 1994; 35: 27-34.
14. Lothman EW. The biochemical basis and pathophysiology of status epilepticus. Neurology 1990; 40(suppl 2): 13-23.
15. Fountain NB, Lothman EW. Pathophysiology of status epilepticus. J Clin Neurophysiol 1995; 12: 326-342.
16. Treiman DM, Walton NY, Kendrick C. A progressive sequence of electroencephalographic changes during generalized convulsive status epilepticus. Epilepsy Res 1990; 5: 49-60.
17. Treiman DM. Generalized convulsive status epilepticus in the adult. Epilepsia 1993; 34(suppl 1): S2-S11.
18. Delgado-Escueta AV, Bajorek JG. Status epilepticus: mechanisms of brain damage and rational management. Epilepsia 1982; 23(suppl 1): S29-S41.
19. Meldrum BS, Vigouroux RA, Brierley JB. Systemic factors and epileptic brain damage. Arch Neurol 1973; 29: 82-87.
20. Corsellis JAN, Bruton CJ. Neuropathology of status epilepticus in humans. In: Delgado-Escueta AV, Wasterlain C, Treiman DM, Porter RJ, Eds. Status epilepticus: basic mechanisms of brain damage and treatment. New York: Raven Press 1983: 129-139 (Advances in neurology, vol 34).
21. Lothman EW, Bertram EH. Epileptogenic effects of status epilepticus. Epilepsia 1993; 34(suppl. 1): S59-S70.
22. DeLorenzo R, Towne A, Ko D et al. Mortality and seizure duration in status epilepticus. Ann Neurol 1987; 22: 132.
23. Treiman DM, Meyers PD, Walton NY et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339: 792-798.
24. Galvin GM, Jelinek GA. Midazolam: an effective intravenous agent for seizure control. Arch Emerg Med 1987; 4: 169-172.
25. Galvin GM, Jelinek GA. Successful treatment of 75 patients in status epilepticus with intravenous midazolam. Emerg Med 1992; 4: 1-55.
26. Kumar A, Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med 1992; 20: 483-488.
27. Rivera R, Segnini M, Baltodano A et al. Midazolam in the treatment of status epilepticus in children. Crit Care Med 1993; 21: 991-994.
28. Parent JM, Lowenstein MD. Treatment of refractory generalized status epilepticus with continuous infusion of midazolam. Neurology 1994; 44: 1837-1840.
29. Lemerle J, Daoud P, Moutard ML et al. Utilisation du midazolam intraveineux dans l'etat de mal convulsif de l'enfant. Arch Pediatr 1995; 2: 848-853.
30. Gherpelli JLD, Luccas FJC, Roitman I et al. Midazolam for treatment of refractory neonatal seizures. Arq Neuropsiquiatr 1994; 52: 260-262.
31. Jawad S, Oxley J, Wilson J et al. A pharmacodynamic evaluation of midazolam as an antiepileptic compound. J Neurol Neurosurg Psychiatry 1986; 49: 1050-1054.
32. Ghilain S, Van Rijckevorsel-Harmant K, Harmant J et al. Midazolam in the treatment of epileptic seizures (letter). J Neurol Neurosurg Psychiatry 1988; 51: 732.
33. Lahat E, Aladjem M, Eshel G et al. Midazolam in treatment of epileptic seizures. Pediatr Neurol 1992; 8: 215-216.
34. McDonagh TJ, Jelinek GA, Galvin GM. Intramuscular midazolam rapidly terminates seizures in children and adults. Emerg Med 1992; 4: 77-81.
35. Mayhue FE. IM midazolam for status epilepticus in emergency department. Ann Emerg Med 1988; 17: 643-645
36. Wroblewski BA, Joseph AB. The use of intramuscular midazolam for acute seizure cessation or behavioral emergencies in patients with traumatic brain injury. Clin Neuropharmacol 1992; 15: 44-49.
37. Product information. Nutley, NJ: Hoffmann-LaRoche, 1994.
38. Higgens TL, Yared JP, Estafanous FG et al. Propofol versus midazolam for intensive care unit sedation after coronary artery bypass grafting. Crit Care Med 1994; 22: 1415-1423.
39. Shapiro JM, Westphal LM, White PF et al. Midazolam infusion for sedation in the intensive care unit: effect on adrenal function. Anesthesiology 1986; 64: 394-398.
40. Shelly MP, Sultan MA, Bodenham A et al. Midazolam infusions in critically ill patients. Eur J Anaesthesiol 1991; 8: 21-27.
41. Shafer A. Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens. Crit Care Med 1998; 26: 947-956.
42. Massanari M, Novitsky J, Reinstein LJ. Paradoxical reactions in children associated with midazolam use during endoscopy. Clin Pediatr 1997; 36: 681-684.
43. Crevoisier PC, Eckert M, Heizmann P et al. Relation entre l'effet clinique et la pharmacocinetique du midazolam apres administration iv et im. Arzneim-Forsch/Drug Res 1981; 31: 2211-2215.
44. Amrein R, Hetzel W. Pharmacology of drugs frequently used in ICUs: midazolam and flumazenil. Intens Care Med 1991; 17: S1-S10.
45. Bell DM, Richards G, Dhillon S et al. A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. Epilepsy Res 1991; 10: 183-190.
46. Serrano EE, Roye DB, Hammer KM et al. Plasma diphenylhydantoin values after intramuscular administration of diphenylhyndantoin. Neurology 1973; 23: 311-317.
47. Carrougher JG, Kadakia S, Shaffer RT et al. Venous complications of midazolam versus diazepam. Gastrointest Endosc 1993; 39: 396-399.
48. Yaffe K, Lowenstein DH. Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus. Neurology 1993; 43: 895-900.
49. Rose B. Barbiturate therapy for status epilepticus in the postanesthesia care unit. J Post Anesth Nurs 1994; 9: 334-339.
50. Arendt RM, Greenblatt DJ, Liebisch DC et al. Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity. Psychopharmacology 1987; 93: 72-76.